

VIJOICE

PRIOR AUTHORIZATION REQUEST

PRESCRIBER FAX FORM

Only the prescriber may complete this form. This form is for prospective, concurrent, and retrospective reviews.

The following documentation is **REQUIRED**. Incomplete forms will be returned for additional information. For formulary information please visit www.myprime.com. Start saving time today by filling out this form electronically. Visit covermymeds.com to begin using this free service.

What is the priority level of this request?

- Standard review
- Expedited/Urgent review – prescriber certifies that waiting for a standard review could seriously harm the patient's life, health or ability to regain maximum function

Today's Date: _____

PATIENT AND INSURANCE INFORMATION

Date of Service (if differs from Today's Date): _____

Patient Name (First):	Last:	M:	DOB (mm/dd/yyyy):
Patient Address:	City, State, Zip:	Patient Telephone:	
Member ID Number:	Group Number:		

PRESCRIBER/CLINIC INFORMATION

Prescriber Name:	Prescriber NPI#:	Specialty:	Contact Name:
Clinic Name:	Clinic Address:		
City, State, Zip:	Phone #:	Secure Fax #:	

PLEASE ATTACH ANY ADDITIONAL INFORMATION THAT SHOULD BE CONSIDERED WITH THIS REQUEST

Patient diagnosis:

- PIK3CA-Related Overgrowth Spectrum (PROS)
- Other (ICD code and description): _____

Medication Requested:	Strength:
-----------------------	-----------

Dosing Schedule:	Quantity per Month:
------------------	---------------------

- For all requests:**
1. Is the patient currently treated with the requested agent? Yes No
 2. Does the patient have any FDA labeled contraindications to the requested agent? Yes No
If yes, please specify contraindications to the requested agent: _____
 3. Is the patient's age within FDA labeling for the requested diagnosis for the requested agent? Yes No
If no, please provide support for using the requested agent for the patient's age for the requested indication: _____
 4. Does the requested quantity (dose) exceed the maximum FDA labeled dose for the requested indication? Yes No
If no, can the requested quantity (dose) be achieved with a lower quantity of a higher strength that does not exceed the program quantity limit? Yes No
If yes, please explain why the requested dose cannot be optimized: _____
 5. Is the prescriber a specialist in the area of patient's diagnosis (e.g., experienced in PROS) or has the prescriber consulted with a specialist in the area of the patient's diagnosis? Yes No
 6. Does the patient have severe manifestations of PROS that requires systemic therapy? Yes No
 7. Does the patient have a diagnosis of PIK3CA-Related Overgrowth Spectrum (PROS) confirmed by ALL of the following: 1) presence of somatic PIK3CA mutation (medical records required for review), 2) congenital or early childhood onset, AND 3) overgrowth sporadic and mosaic? **Please note, lab results and medical records are required.** Yes No
If yes, does the patient have at least TWO of the following features: 1) overgrowth, 2) vascular malformations, and/or 3) epidermal nevus? Yes No
 8. If no, does the patient have at least ONE of the following features: 1) large isolated lymphatic malformations, 2) isolated macrodactyly OR overgrown splayed feet/hands, overgrown limbs, 3) truncal adipose overgrowth, 4) Hemimegalencephaly (bilateral)/dysplastic megalencephaly/focal cortical dysplasia, 5) epidermal nevus, 6) seborrhic keratoses, and/or 7) benign lichenoid keratoses? Yes No

Please continue to the next page.

Patient Name (First):	Last:	M:	DOB (mm/dd/yyyy):
For renewal requests: 9. Has the patient had clinical benefit with the requested agent?..... <input type="checkbox"/> Yes <input type="checkbox"/> No 10. Has the patient had disease progression (e.g., increase in lesion number, increase in lesion volume) with the requested agent? Please note, medical records are required. <input type="checkbox"/> Yes <input type="checkbox"/> No			
Please fax or mail this form to: Prime Therapeutics LLC Clinical Review Department 2900 Ames Crossing Road Suite 200 Eagan, MN 55121 TOLL FREE		CONFIDENTIALITY NOTICE: This communication is intended only for the use of the individual entity to which it is addressed, and may contain information that is privileged or confidential. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please return the original message to Prime Therapeutics via U.S. Mail. Thank you for your cooperation.	
Phone: BCBSIL: 800.285.9426 BCBSMT: 888.723.7443 BCBSNM: 800.544.1378 BCBSOK: 800.991.5643 BCBSTX: 800.289.1525		Fax: 877.243.6930	